Sarepta Therapeutics (SRPT) Tops Q3 EPS by 76c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.46), $0.76 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $331.8 million versus the consensus estimate of $285.83 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
• Holcim to acquire Fermacell from James Hardie for EUR 840M